Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain:phosphotyrosine mimetics exploiting multifunctional group replacement chemistry
- PMID: 14991680
- DOI: 10.1002/bip.10600
Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain:phosphotyrosine mimetics exploiting multifunctional group replacement chemistry
Abstract
A series of novel nonpeptide inhibitors of the pp60(c-Src) (Src) SH2 domain is described that exploit multifunctional group replacement of the phenylphosphate moiety of phosphotyrosine (pTyr). Relative to an x-ray structure of citrate complexed to the pTyr binding site of the Src SH2 domain, these nonpeptide ligands illustrate the systematic replacement of the phosphate group by multiple nonhydrolyzable, mono- or dianionic functionalities. Specifically, several phenylalanine (Phe) analogs incorporating key 4' and 3' substituents were synthesized and incorporated into a bicyclic benzamide template previously reported (W. C. Shakespeare et al., Proceedings of the National Academy of Science USA, 2000, Vol. 97, pp. 9373-9378). These pTyr mimetics included 4',3'-diphosphono-Phe (Dpp), 4',3'-dicarboxymethyloxy-Phe (Dcp), and 4'-phosphono-3'-carboxymethyloxy-Phe (Cpp). Noteworthy were nonpeptide inhibitors 8-11 that were 5- to 10-fold more potent than the cognate tetrapeptide ligand Ac-pTyr-Glu-Glu-Ile-NH(2) in binding to the Src SH2 domain.
Copyright 2004 Wiley Periodicals, Inc.
Similar articles
-
Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding.J Med Chem. 2004 Jun 3;47(12):3131-41. doi: 10.1021/jm040008+. J Med Chem. 2004. PMID: 15163193
-
A novel phosphotyrosine mimetic 4'-carboxymethyloxy-3'-phosphonophenylalanine (Cpp): exploitation in the design of nonpeptide inhibitors of pp60(Src) SH2 domain.Bioorg Med Chem Lett. 2001 Sep 3;11(17):2319-23. doi: 10.1016/s0960-894x(01)00446-2. Bioorg Med Chem Lett. 2001. PMID: 11527723
-
Design of tetrapeptide ligands as inhibitors of the Src SH2 domain.Bioorg Med Chem. 2004 Feb 15;12(4):779-87. doi: 10.1016/j.bmc.2003.10.060. Bioorg Med Chem. 2004. PMID: 14759738
-
Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors.Biopolymers. 2001;60(1):32-44. doi: 10.1002/1097-0282(2001)60:1<32::AID-BIP1002>3.0.CO;2-I. Biopolymers. 2001. PMID: 11376431 Review.
-
Grb2 SH2 domain-binding peptide analogs as potential anticancer agents.Biopolymers. 2003;71(2):132-40. doi: 10.1002/bip.10396. Biopolymers. 2003. PMID: 12767115 Review.
Cited by
-
Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance.Cancers (Basel). 2024 Aug 2;16(15):2754. doi: 10.3390/cancers16152754. Cancers (Basel). 2024. PMID: 39123481 Free PMC article. Review.
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data.Clin Investig (Lond). 2011 Dec 1;1(12):1695-1706. doi: 10.4155/cli.11.150. Clin Investig (Lond). 2011. PMID: 22384312 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous